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Abstract Secretory phospholipase A2 (sPLA2) has been re-
ported to be involved in cell proliferation in general and in
endothelial cell migration, processes required for capillary for-
mation. Subsequently, we examined the potential control of an-
giogenesis by sPLA2 inhibition, using a cell-impermeable sPLA2
inhibitor composed of N-derivatized phosphatidyl-ethanolamine
linked to hyaluronic acid. This inhibitor e¡ectively inhibits the
proliferation and migration of human bone marrow endothelial
cells in a dose-dependent manner, and suppresses capillary for-
mation induced by growth factors involved in vascularization of
tumors and of atherosclerotic plaques. It is proposed that
sPLA2 inhibition introduces a novel approach in the control of
cancer development and atherosclerosis. ' 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The development of primary tumors and metastatic lesions
is dependent on angiogenesis, which is initiated by the migra-
tion of endothelial cells to the newly formed tumor and their
proliferation [1]. The formation of new blood vessels is also
involved in the progression of atherosclerotic plaques and its
fragility and rupture, which is the main cause of acute ische-
mic events [2,3]. Accordingly, the control of angiogenesis, by
inhibiting endothelial cell proliferation and migration, has
been sought for anticancer therapy [4], and for vascular pro-
tection [5].
Phospholipase A2 (PLA2) constitutes a family of enzymes
that in mammalian cells includes the secretory (sPLA2), the
intracellular cytosolic (cPLA2) and calcium-independent
PLA2. These enzymes hydrolyze cell membrane phospholipids
to produce lyso-phospholipids (lyso-PL) and free fatty acids,
among them arachidonic acid (AA). These are potent media-
tors of diverse pathological processes, including in£ammation
[6,7], tumor growth and metastasis [8,9] : lyso-PL, in particu-
lar lyso-phosphatidic acid, acts as a growth factor and induces
cancer cell proliferation [10]. AA is metabolized in mamma-
lian cells to form the eicosanoids, mainly via the cyclooxyge-
nase (COX) pathway, producing prostaglandins and throm-
boxanes, and the lipoxygenase (LOX) pathway, producing
leukotrienes and hydroxyeicosatetraenoic acids [11].
AA and its metabolites are involved in the development of
several types of cancer in humans, including colon, breast,
gastric and hepatocellular carcinomas [12^15]. Eicosanoids
derived from both COX and LOX pathways have been shown
to facilitate the invasiveness of tumor cells, and to induce
tumor vascularization [16,17]. Indeed, a number of studies
have suggested that PLA2 activity plays an important role
in growth factor-induced endothelial cell migration, either di-
rectly or via the production of AA derivatives. For instance,
the angiogenic activity of the in£ammatory cytokine oncosta-
tin M (OSM) is related to COX2 expression, as it can be
suppressed by COX2 inhibitors [18]. It has been shown that
the COX-2-induced metabolites of AA speci¢cally [thrombox-
ane A2, prostaglandin (PG) PGE2 and PGI2] facilitate endo-
thelial cell migration and growth factor-induced angiogenesis
[19]. Although cPLA2 is speci¢c to AA-carrying phospholip-
ids, in activated cells and pathological conditions the majority
of AA is produced primarily by sPLA2 [20]. In addition,
sPLA2, secreted into plasma and body £uids by activated
white cells, induces cell proliferation via a binding-mediated
process [21]. It has also been reported that PLA2 activity,
particularly that of sPLA2, is required for basic ¢broblast
growth factor (bFGF)-induced endothelial cell motility, as it
can be suppressed by sPLA2 inhibitors [22,23]. Therefore, it
seems that sPLA2 is involved in tumor vascularization in more
than one way.
Accordingly, inhibition of sPLA2 activity has been pro-
posed for the control of related pathological states [24^27],
and a number of inhibitors have been proposed for this pur-
pose. However, inhibitors that penetrate into the cell might
impair the vital phospholipid metabolism and the cell viabil-
0014-5793 / 02 / $22.00 H 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 9 0 7 - 1
*Corresponding author. Fax: (33)-1-4326273.
E-mail address: jeannette.soria@htd.ap-hop-paris.fr (J. Soria).
Abbreviations: AA, arachidonic acid; bFGF, basic ¢broblast growth
factor; COX, cyclooxygenase; ExPLI, extracellular PLA2 inhibitor;
FCS, fetal calf serum; HBMEC, endothelial cells from human bone
marrow; HyAc, hyaluronic acid; HyPE, N-derivatized phosphatidyl-
ethanolamine linked to hyaluronic acid; LOX, lipoxygenase; Lyso-
PL, lyso-phospholipids; MVGS, microvascular growth supplement;
OSM, oncostatin M; PG, prostaglandin; PLA2, phospholipase A2 ;
sPLA2, secretory phospholipase A2 ; VEGF, vascular endothelial
growth factor
FEBS 26215 19-6-02
FEBS 26215 FEBS Letters 522 (2002) 113^118
ity. Consequently, it has been suggested that an inhibitor of
PLA2 activity at the cell membrane, which does not enter the
cell, is more suitable for therapeutic purposes [25,27].
Extracellular PLA2 inhibitors (ExPLIs) which ful¢ll these
requirements have been designed and synthesized in the lab-
oratory of S. Yedgar, by the binding of PLA2 inhibitors to
polymeric carriers of di¡erent molecular weights [27,28]. This
was done in a way that enables the inhibiting molecule to
control the PLA2 activity at the cell membrane, but its inter-
nalization is prevented by the polymeric carrier. The ExPLIs
have been found e¡ective in protecting cells from the action of
di¡erent types of sPLA2 enzymes [28] as well as activation of
endogenous sPLA2 by in£ammatory mediators [29,30].
In the present study, we have examined the potential use of
ExPLIs, as a prototype for cell-impermeable sPLA2 inhibitors,
for the control of angiogenic processes [1,4]. For this purpose
we determined the ExPLI e¡ect on the proliferation and mi-
gration of, and capillary formation by human bone marrow
endothelial cells (HBMEC), induced by the angiogenic factors
bFGF and vascular endothelial growth factor (VEGF), in-
volved in tumor vascularization, as well as OSM, involved
in neovascularization of atherosclerotic plaques [31,32].
2. Materials and methods
2.1. Materials
Endothelial cells from human bone marrow (HBMEC) were estab-
lished by transfecting human bone marrow endothelial cells with SV40
large T antigen for immortalization. They are kindly provided by Dr.
Kenneth J. Pienta (Cancer center, Ann Harbor, MI, USA). Cells were
cultured in complete M131 medium (Cascade Biologics) supplemented
with 10% fetal calf serum (FCS), 5% microvascular growth supple-
ment (MVGS) which contains 5% FCS, hydrocortisone, human
bFGF, heparin, human epidermal growth factor and dibutyryl
cAMP (Cascade Biologics), 1% L-glutamine, 100 IU/ml penicillin
and 100 Wg/ml streptomycin.
The ExPLI employed in the present study was composed of hyal-
uronic acid-linked N-derivatized phosphatidyl-ethanolamine (HyPE),
designed and synthesized in the laboratory of S. Yedgar, by truncat-
ing hyaluronic acid (Gideon Richter, Budapest, Hungary) to a MW of
50^100 kDa, and linking it to the amino head group of dipalmitoyl-
phosphatidyl-ethanolamine (PE) [29].
2.2. Cell proliferation assay
For the proliferation assay, we used the minimal concentration of
FCS (7.5%) to allow su⁄cient viability of endothelial cells. Brie£y,
after trypsinization, the cells were seeded at a concentration of 5U104
cells in each well of 24-well plates (Nunc, Denmark) and then incu-
bated without or with cytokines (25 ng/ml bFGF, 20 ng/ml VEGF or
2.5 ng/ml OSM). HyPE was added at concentrations indicated in
Section 3. After incubation for 2 days, cells were detached by trypsin
(0.05% w/v; Sigma), resuspended in Isoton II solution (Coulter,
France) and counted in a particle counter (CoulterZ1, Coultronics).
Hyaluronic acid (HyAc) was used as control.
2.3. Cell migration by wound healing method
Endothelial cells were cultured in 24-well culture plates. After
reaching 80% con£uence, HBMEC were dislodged by a cell scraper
under standard conditions, as previously described [33]. After three
times washing the cells with phosphate-bu¡ered saline, the cells were
incubated in complete M131 medium in the presence of increasing
HyPE concentration (HyAc was used as control). Cell migration
was determined by measuring the number of cells migrating into 10
mm2 ‘wounding area’, 18 h after introducing ‘the wound’ into the
con£uent monolayer.
2.4. Formation of capillary tubes in a model of angiogenesis in
¢brin gels
HBMEC were embedded in ¢brin matrix, which mimics the in vivo
situation where ¢brin appears to be a common component of the
matrix present at sites of in£ammation and/or tumor stroma. This
model with microcarrier beads was devised according to the method
of Nehls et al. [33]. Brie£y, HBMEC were allowed to attach to the
Cytodex-3 microcarrier beads (Sigma) by incubating cells with beads
in M131 containing 10% FCS. The beads were then embedded in a
¢brin matrix, obtained by coagulation of a solution of puri¢ed ¢brin-
ogen at 8 mg/ml in M131 containing 0.2 mM aprotinin, 10% FCS.
After addition of thrombin (2 U/ml, ¢nal concentration), ¢brin gel
was formed, and then 500 Wl of complete culture medium containing
10% FCS, 5% MVGS was added. Formation of capillary tubes evolv-
ing from the surface of the microcarrier beads could be observed after
3 days culture. These capillaries were photographed, the lengths and
widths of capillary tubes were measured using the microvision Saisam
program (Microvision, Evry, France) on a reverse microscope. Capil-
lary formation was induced by the addition of bFGF (25 ng/ml ¢nal
concentration), or VEGF (20 ng/ml ¢nal concentration), or OSM (2.5
ng/ml ¢nal concentration) to the ¢brin gel (containing 10% FCS).
The e¡ect of HyPE on the capillary formation was examined in two
ways: (1) HyPE (20 WM) was added to the ¢brin simultaneously with
the HBMEC-coated beads and growth factors; (2) HyPE was added
after interaction of the cells with the growth factors, to rule out the
possibility that HyPE interferes with the interaction of the growth
factors with the cell surface. Speci¢cally, HBMEC-coated beads
were incubated with the growth factors for a period of 3 h, after
which they were washed and incorporated into the ¢brin gel contain-
ing HyPE (20 WM).
2.5. Statistical tests
Signi¢cance values were determined using the two tailed non-para-
metric Mann^Whitney and Wilcoxon test using Instat software. All
results are expressed as the mean valueTS.E.M. P6 0.05 was re-
garded as signi¢cant statistical di¡erence.
3. Results
To comprehensively study the possible control of angiogen-
ic processes by inhibition of sPLA2 activity, we determined
the e¡ect of HyPE on HBMEC proliferation, migration and
capillary formation. As noted in Section 2, the medium used
for cultivation of the endothelial cells is already supplemented
with growth factors. To examine the e¡ect of HyPE on
growth factor-induced endothelial cell activation, we further
supplemented the culture medium with bFGF, VEGF and
OSM, which further increased HBMEC stimulation by about
50%, as shown below.
3.1. E¡ect of HyPE on HBMEC proliferation
Fig. 1 shows that HyPE e¡ectively inhibited HBMEC pro-
liferation in a dose-dependent manner, whether the cells were
grown in the control culture medium containing standard
amount of growth factors, or stimulated with additional
amount of VEGF, bFGF or OSM. At the same time, HyAc
did not a¡ect the cell proliferation (not shown). It should be
Table 1
Inhibitory e¡ect induced by HyPE on endothelial cell migration by
wound healing method
Number of migrated cells
HBMEC 68T7 (complete wound healing)
HBMEC+HyPE 2.5 WM 64T9 (complete wound healing)
HBMEC+HyPE 5 WM 37T5 (incomplete wound healing)***
HBMEC+HyPE 10 WM 13T6***
HBMEC+HyPE 20 WM 8T3***
After cell scraping, the cells were incubated in complete M131 me-
dium in the absence or presence of HyPE at indicated ¢nal concen-
trations. After 18 h incubation, cells that migrated in 10 mm2
wounding area were counted. Results of three experiments in dupli-
cate (meanTS.E.M.). ***P6 0.005 as compared with control.
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noted that HyPE did not induce a toxic e¡ect in the endothe-
lial cells.
3.2. E¡ect of HyPE on HBMEC migration
HBMEC displacement was monitored following wound for-
mation for 18 h, by determining the migration of the cells in
the wounded area. The results, presented in Table 1, show
that this period of time was su⁄cient for complete wound
covering in normal conditions, but the addition of HyPE ex-
erted a dose-dependent inhibition of HBMEC migration.
3.3. E¡ect of HyPE on capillary formation by HBMEC
To study the e¡ect of HyPE on tube formation, HBMEC
were cultured on microcarrier beads until they covered the
whole bead surface. The beads were embedded in a ¢brin
matrix and cultivated for 3 days in the control or growth
factor-supplemented culture medium. The formation of the
HBMEC-derived hollow tube-like structures was visualized
and their capillary length was determined as described in Sec-
tion 2.
Results presented in Fig. 2 show that tube formation in
¢brin matrix was enhanced by all angiogenic factors (bFGF,
VEGF, and OSM), but this was strongly suppressed by HyPE
both in control and in growth factor-supplemented medium.
HyAc did not modify the capillary tube formation in both
control and stimulated conditions. As shown in Table 2,
HyPE clearly decreased the tube dimensions, in particular
their length.
As described above, the ExPLIs are composed of an inhib-
iting lipid moiety (PE) which incorporates into the cell mem-
brane and anchors the polymeric carrier (HyAc) to the cell
surface. This raises the possibility that the observed inhibitory
e¡ect might be due to interference of the polymeric carrier
with the accessibility of the growth factors to the cell surface.
To examine this possibility, HBMEC cultured on the micro-
carrier beads were ¢rst stimulated with the growth factors for
3 h (to allow interaction with their receptors at the cell sur-
face), then washed to remove the unbound growth factors and
introduced into HyPE-containing ¢brin matrix. As shown in
Fig. 3, under these conditions, capillary tube formation was
Fig. 1. Inhibitory e¡ect induced by HyPE on bFGF-, VEGF- and OSM-stimulated HBMEC proliferation. 50U103 HBMEC-1 were seeded, in-
cubated for 2 days with a minimal concentration of FCS (7.5%) to assure viability of the cells with indicated concentrations of HyPE, and
with or without addition of angiogenic factors. Then cells in each well were then counted in a particle counter. Results of four experiments in
duplicate, expressed as meanTS.E.M. per well. ***P6 0.001, **P6 0.01, *P6 0.05, in comparison to cells without HyPE.
Table 2
Inhibitory e¡ect induced by HyPE on bFGF-, VEGF- and OSM-stimulated capillary tube formation in a three-dimensional ¢brin gel
Length (meanTS.E.M.) (Wm) Width (meanTS.E.M.) (Wm)
3HyPE +HyPE 3HyPE +HyPE
Control 232.23T 56.13 80.31T30.59*** 9.42T1.65 8.32T1.47
bFGF 533.92T 65.02 266.73T23.17*** 15.83T2.96 11.21T1.52*
VEGF 511.09T 72.05 215.68T31.22*** 14.86T1.46 9.32T1.18**
OSM 518.82T 58.49 234.85T36.32*** 16.89T1.89 10.02T1.00***
***P6 0.005, **P6 0.01, *P6 0.05.
Results of three experiments and for each experiment, ¢ve beads were examined. Selected beads were those for which the capillary tubes are
the best.
Microcarrier beads coated with HBMEC were embedded in ¢brin matrix in the presence or absence of HyPE (20 WM, ¢nal concentration) and
growth factors (25 ng/ml bFGF, 20 ng/ml VEGF or 2.5 ng/ml OSM), as indicated in Section 2. After 3 days culture, in the presence or absence
of HyPE the lengths and widths of capillary tubes were measured using a microvision program.
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e¡ectively suppressed by HyPE, suggesting that the HyPE
e¡ect is not due to a defective growth factor accessibility
due to steric hindrance by the polymer at the cell surface of
the endothelial cells.
4. Discussion
Previous studies have suggested a role for sPLA2 in cell
motility. Rizzo et al. [23], testing the e¡ect of several sPLA2s
on bovine aortic endothelial cells, found that an sPLA2 inhib-
itor markedly decreased this endothelial cell migration, and
proposed that sPLA2 plays a physiological role in this pro-
cess. Similarly, Sa et al. [22] showed that the stimulating e¡ect
of bFGF on wound-induced movement of bovine aortic en-
dothelial cells was markedly reduced by pharmacological in-
hibition of PLA2, suggesting that bFGF-induced cell migra-
tion involves PLA2 activity.
The results of the present study demonstrate that the extra-
cellular sPLA2 inhibitor, HyPE, is a potent regulator of sev-
eral essential processes required for angiogenesis, speci¢cally,
proliferation and migration of human endothelial cells and
capillary formation induced by growth factor which are in-
volved in vascularization of tumors (bFGF, VEGF) and ath-
erosclerotic plaque (OSM) [31,32]. The suppression of capil-
Fig. 2. Inhibitory e¡ect induced by HyPE on capillary tube formation in a three-dimensional ¢brin gel in conditions where growth factors,
HyPE (20 WM) or HyAc were added to ¢brin simultaneously with HBMEC-1-coated beads. Row A: control; row B: bFGF (25 ng/ml);
row C: VEGF (20 ng/ml); row D: OSM (2.5 ng/ml). Column 1: without HyPE; column 2: HyPE 20 WM; column 3: HyAc 20 WM.
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lary formation was obtained whether HyPE was added prior
to or after stimulation of the cells with the growth factors.
Together with the ¢nding that HyAc alone did not a¡ect
capillary formation, this suggests that HyPE exerts its inhib-
itory e¡ect not by hindering the accessibility of the growth
factors to the cell surface, but rather by interfering in the
signaling process initiated by the growth factors, although
the exact mechanism(s) of their e¡ect remains to be elabo-
rated. Taken together, these ¢ndings provide support for the
key role of sPLA2 in the pathophysiology relating to stimu-
lated angiogenesis and organ vascularization.
Endothelial cell proliferation and angiogenesis involved the
participation of various lipid mediators, including lyso-LPs
and di¡erent eicosanoids, the production of which is initiated
by PLA2. Therefore, by suppressing membrane lipid hydroly-
sis [28,30], the ExPLIs have the potential to control angiogen-
esis, by regulating the production of more than one mediator.
All in all, the results and considerations presented in the
present study support the regulating role of involvement of
sPLA2 in processes, present the ExPLIs as cell-impermeable
PLA2 inhibitors for the control of angiogenesis, thus intro-
ducing a novel approach in the research and possibly therapy
of cancer and other pathological conditions involving organ
vascularization.
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